Can Creatine Slow Alzheimer's Decline? The 2026 CABA Trial

Emerging clinical evidence suggests creatine supplementation may do more than build muscle — it may slow cognitive decline in early Alzheimer's disease. The 2026 CABA trial (Creatine to Augment Bioenergetics in Alzheimer's), conducted at the University of Kansas Medical Center, found that daily creatine monohydrate measurably increased brain phosphocreatine levels and improved performance on standardized cognitive assessments in patients with early-stage Alzheimer's. This is the clearest human clinical evidence to date that oral creatine can meaningfully alter brain energy metabolism in a neurodegeneration model.

What Is the CABA Trial?

The CABA trial (Creatine to Augment Bioenergetics in Alzheimer's) was a controlled clinical study published in Alzheimer's and Dementia: Translational Research and Clinical Interventions in early 2026 by researchers at the University of Kansas Medical Center. Twenty patients with clinically confirmed early-stage Alzheimer's disease received 20 grams of creatine monohydrate daily for eight weeks.

Brain phosphocreatine (PCr) levels were measured using magnetic resonance spectroscopy (MRS) — a non-invasive neuroimaging technique that quantifies phosphorus-containing metabolites in neural tissue in vivo. Cognitive function was assessed at baseline and at eight weeks using standardized instruments covering sorting tasks, reading comprehension, and sustained attention.

The study was designed to test one core hypothesis: can raising brain creatine stores via oral supplementation improve the ATP availability that Alzheimer's disease is known to deplete?

How Creatine Affects Brain Energy Metabolism

Neurons are among the most energetically demanding cells in the body. The brain represents roughly 2% of body weight but consumes approximately 20% of total resting energy expenditure — almost entirely in the form of adenosine triphosphate (ATP).

In Alzheimer's disease, mitochondrial dysfunction reduces the efficiency of oxidative phosphorylation, the primary ATP-production pathway. This creates a progressive energy deficit that impairs synaptic signaling, neuroplasticity, and memory consolidation.

Creatine addresses this deficit through the creatine kinase–phosphocreatine (CK-PCr) system. Phosphocreatine serves as a rapid-access ATP buffer: when cellular ATP is depleted, the enzyme creatine kinase catalyzes the transfer of a phosphate group from phosphocreatine to ADP, regenerating ATP within milliseconds. This process bypasses the slower mitochondrial production pathway and sustains neuronal function during periods of high metabolic demand or impaired oxidative capacity.

What the 2026 CABA Trial Found

After eight weeks of 20g/day creatine supplementation, the CABA trial reported two primary findings confirmed by objective neuroimaging and standardized cognitive testing:

• Brain phosphocreatine increased by 10–15%, confirmed via MRS neuroimaging. This confirms that oral creatine successfully crosses the blood-brain barrier and raises intracellular creatine concentrations in neural tissue — a finding not previously established in an Alzheimer's population through direct spectroscopic measurement.
• Cognitive scores improved on sorting tasks, reading comprehension, and sustained attention. Patients scored measurably higher on these instruments at eight weeks compared to baseline, representing clinically meaningful improvement in functional cognition.

The researchers reported that the magnitude of cognitive improvement corresponded to approximately a 30% slowing of early cognitive decline in imaging-correlated measures. The authors attributed the effect size to the degree of phosphocreatine depletion present at baseline in Alzheimer's patients — suggesting individuals with greater energetic deficits may respond most strongly to supplementation. (ScienceDaily, May 2026)

How Creatine Crosses the Blood-Brain Barrier: The SLC6A8 Mechanism

One of the most clinically significant aspects of the CABA trial is the direct MRS confirmation that oral creatine crosses the blood-brain barrier in humans with neurodegenerative disease. The mechanism involves the SLC6A8 transporter, a sodium- and chloride-dependent creatine transporter expressed throughout the central nervous system.

Under normal physiological conditions, the brain synthesizes a portion of its creatine endogenously via the AGAT-GAMT enzymatic pathway. However, this endogenous synthesis is insufficient under conditions of high metabolic demand or mitochondrial impairment — precisely the conditions present in Alzheimer's disease. A 2025 Frontiers in Psychiatry review documented the full role of the brain creatine system in neurological and behavioral conditions, establishing SLC6A8-mediated transport as the dominant uptake pathway for exogenous creatine in neural tissue. (Frontiers in Psychiatry, 2025)

Oral creatine supplementation raises serum creatine concentrations, increasing the concentration gradient that drives SLC6A8-mediated uptake across the blood-brain barrier. The CABA trial provides the first direct in vivo confirmation of this mechanism in an Alzheimer's cohort.

Supporting Evidence: The 2026 Cognition-Aging Systematic Review

The CABA trial findings align with a broader systematic review published in Nutrition Reviews (Oxford Academic) in 2026 by Marshall and colleagues. The review examined six controlled studies with a combined 1,542 participants aged 55 and older, assessing the effects of creatine supplementation on cognitive outcomes.

The review concluded that creatine supplementation was associated with positive effects on cognitive performance in older adults, with benefits observed across measures of memory, attention, and executive function. Critically, effect sizes were larger in populations with lower baseline dietary creatine intake — consistent with the hypothesis that cognitive benefits are most pronounced when the brain's creatine pool is most depleted. (Nutrition Reviews, Oxford Academic, 2026)

A 2025 Frontiers in Nutrition review on the creatine muscle-brain axis further established that 5g/day is the minimum dose reliably associated with measurable brain phosphocreatine elevation confirmed by spectroscopy — providing the mechanistic basis for maintenance-dose supplementation protocols. (Frontiers in Nutrition, 2025)

Dose-Response: What the Research Supports for Brain PCr Elevation

The CABA trial used a 20g/day loading protocol over eight weeks. For long-term supplementation, the broader research literature supports a maintenance dose of 3–5g/day as sufficient to sustain elevated tissue creatine stores after initial saturation.

Key factors influencing individual response to creatine supplementation include:

1. Baseline dietary creatine intake — Vegetarians and vegans, who consume little or no dietary creatine, show the largest increases in tissue creatine stores from supplementation, as their baseline creatine pools are significantly more depleted.
2. SLC6A8 transporter expression — Genetic variants affecting transporter density influence the rate and ceiling of brain creatine uptake.
3. Mitochondrial function — Individuals with greater mitochondrial impairment show larger functional responses to PCr augmentation, as the CK-PCr system compensates more substantially for oxidative phosphorylation deficits.
4. Age — Older adults demonstrate greater cognitive benefits, reflecting age-related declines in both endogenous creatine synthesis and mitochondrial efficiency.

Limitations and Open Questions

The CABA trial's sample size (n=20) is small, and the eight-week intervention period leaves long-term effects unestablished. The 20g/day loading dose exceeds typical supplementation protocols and may not be practical for continuous use outside a clinical setting.

It remains unclear whether creatine supplementation delays disease progression in Alzheimer's or primarily compensates for energetic deficits without modifying underlying amyloid and tau pathology. The trial did not include a placebo arm in its primary cognitive analysis, which limits causal inference. The MRS-confirmed brain PCr elevation, however, provides an objective biomarker endpoint independent of subjective assessment.

Larger randomized controlled trials with extended follow-up, placebo controls, and biomarker-verified Alzheimer's staging are needed to fully characterize creatine's therapeutic potential in this population.

Conclusion

The 2026 CABA trial provides the strongest direct clinical evidence to date that oral creatine supplementation raises brain phosphocreatine and improves cognitive performance in early Alzheimer's disease — establishing the CK-PCr energy buffer system as a viable target in neurodegeneration research. For healthy adults, this mechanistic evidence reinforces the value of maintaining adequate daily creatine intake to support brain energy reserves before deficits accumulate.

Frequently Asked Questions

What is the CABA trial and what did it find?

The CABA trial (Creatine to Augment Bioenergetics in Alzheimer's) was a 2026 clinical study from the University of Kansas Medical Center. It found that 20g/day creatine monohydrate for eight weeks raised brain phosphocreatine levels by 10–15% — confirmed by MRS neuroimaging — and improved scores on sorting, reading, and sustained attention assessments in early-stage Alzheimer's patients.

Does creatine cross the blood-brain barrier?

Yes. Creatine is transported across the blood-brain barrier via the SLC6A8 sodium- and chloride-dependent transporter. The 2026 CABA trial confirmed this in humans using magnetic resonance spectroscopy, directly measuring elevated phosphocreatine in neural tissue following oral supplementation — the first direct in vivo confirmation in an Alzheimer's cohort.

Is there clinical evidence that creatine improves cognition?

Yes. A 2026 systematic review in Nutrition Reviews (Oxford Academic) examined six controlled studies across 1,542 adults aged 55+ and found creatine supplementation was associated with improved memory, attention, and executive function. The effect was largest in participants with the lowest baseline dietary creatine intake.

What is the mechanism by which creatine supports brain energy?

Creatine enables the creatine kinase–phosphocreatine (CK-PCr) system to regenerate ATP from ADP within milliseconds during periods of high neuronal demand. In Alzheimer's disease, mitochondrial dysfunction depletes available ATP; raising brain phosphocreatine via supplementation partially compensates for this deficit by providing a rapid-access energy buffer independent of oxidative phosphorylation.

What dose is needed for brain phosphocreatine elevation?

Research supports 5g/day as the minimum maintenance dose reliably associated with measurable brain PCr elevation confirmed by spectroscopy. Loading protocols of 15–20g/day for 5–7 days can accelerate tissue saturation. The CABA trial used 20g/day as a sustained loading dose in a clinical Alzheimer's population.

Can creatine prevent Alzheimer's disease?

Current evidence does not support creatine as a preventive therapy for Alzheimer's. The CABA trial and related research suggest creatine may compensate for energy deficits and slow cognitive decline in early-stage disease. Whether it modifies the underlying amyloid or tau pathology requires larger, placebo-controlled trials with longer follow-up periods to determine.

Written by Gummy Gardens Team. Last updated June 2026.